Chemotherapie: Offener Zugang
Offener Zugang
ISSN: 2167-7700
ISSN: 2167-7700
Dana M Chase, Steven J Gibson, Bradley J Monk and Krishnansu S Tewari
Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted with investigational PARP, HDAC, MEK, topoisomerase and COX-2 inhibitors currently being studied. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity, will be discussed.